Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 372 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: carotenoids Clear all
Completed Phase 2 Interventional Results available

The Effects of Lycopene on High Risk Prostatic Tissue

NCT01443026
View directory record Official record
Conditions
Intraepithelial Prostatic Neoplasia, Prostatic Neoplasms
Interventions
Lycopene 30mg, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

NCT00005576
View directory record Official record
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
Interventions
monoclonal antibody Ch14.18, isotretinoin, aldesleukin, sargramostim
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 3, 2026, 5:39 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

2021 PMT iAge® Intervention Trial by Edifice Health

NCT04983017
View directory record Official record
Conditions
Chronic Inflammation, Inflammaging
Interventions
Dietary supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Edifice Health
Industry
Eligibility
18 Years and older
Enrollment
781 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Greenbrae, California • Suwanee, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586
View directory record Official record
Conditions
Drug Toxicity, Lung Cancer
Interventions
13-cis retinoic acid, Tocopherol
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
4
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 3, 2026, 5:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413
View directory record Official record
Conditions
Multiple Myeloma
Interventions
All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

NCT03033303
View directory record Official record
Conditions
Neuroblastoma
Interventions
Hu3F8, GM-CSF, Isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

NCT00392327
View directory record Official record
Conditions
Anaplastic Medulloblastoma, Medulloblastoma
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Cyclophosphamide, Filgrastim, Isotretinoin, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 22 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
170
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 3 Interventional

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

NCT00078988
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Juice Study: Sensitivity of Skin Carotenoid Status to Detect Change in Intake

NCT03202043
View directory record Official record
Conditions
Overweight
Interventions
High dose vegetable juice, Medium dose vegetable juice, Low dose vegetable juice, Control bottled water
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 3, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

NCT00969722
View directory record Official record
Conditions
Primary Refractory Neuroblastoma
Interventions
MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Months to 13 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 3, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

NCT06358677
View directory record Official record
Conditions
Metastatic Solid Tumor, Locally Advanced Solid Tumor
Interventions
Topical Tretinoin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Yellow Potatoes and Carotenoids

NCT07606001
View directory record Official record
Conditions
Carotenoids
Interventions
Yellow-flesh potatoes, White-flesh potatoes
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Not listed Phase 4 Interventional

A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne

NCT01422785
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2%/tretinoin 0.025% gel alone, clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

NCT01183416
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8 monoclonal antibody and 13-cis-Retinoic Acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 3, 2026, 5:39 PM EDT
Recruiting Phase 1 Interventional

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

NCT05232409
View directory record Official record
Conditions
Cancer Metastatic, Metastatic Solid Tumor
Interventions
Zeaxanthin, Zeaxanthin Plus Pembrolizumab
Biological · Combination Product
Lead sponsor
Valley Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

NCT00002506
View directory record Official record
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00646230
View directory record Official record
Conditions
Neuroblastoma
Interventions
fenretinide, high performance liquid chromatography, pharmacological study
Drug · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
0 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

NCT01047189
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2% and tretinoin 0.025%, clindamycin 1% gel, tretinoin 0.025% cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

NCT00080899
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
fenretinide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

NCT00450749
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 3, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective Study of Topical Adapinoid Versus Topical Retinol

NCT05778760
View directory record Official record
Conditions
Wrinkle
Interventions
Retinol, Adapinoid
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
35 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 3, 2026, 5:39 PM EDT